Methods of predicting patient responsiveness to treatment of attention-deficit/hyperactivity disorder (ADHD) with selective norepinephrine reuptake inhibitors; identifying individuals requiring a higher than normal dose of atomoxetine for treating ADHD; and predicting patient responsiveness to treatment of neuropsychiatric diseases or disorders responsive to treatment with selective norepinephrine reuptake inhibitors are provided. These methods are based on the identification of the variable number of tandem repeats (VNTR) polymorphism present in the 3′-untranslated region of the human dopamine transporter 1 (DAT 1) gene present in patient body fluid or tissue samples. Patients with a 10/10 VNTR genotype are considered poor responders to treatment with atomoxetine and other selective norepinephrine reuptake inhibitors for the indicated conditions.
展开▼